Although additional studies are needed, our results strongly support the recommendations to include aPS/PT Ab as a new laboratory criteria biomarker for the classification of APS, especially in cases where patients have received anticoagulant treatment, since aPS/PT Ab are not affected by anticoagulant therapy and may be a substitute for LA determination. This evidence concerns the gene F2 and autoimmune polyendocrinopathy.